Shares of Cell Therapeutics Inc. tumbled 39.6 percent after FDA briefing documents, emerging ahead of Wednesday's advisory panel, suggested that the company's abbreviated pivotal study of pixantrone might not be enough to warrant the drug's accelerated approval in relapsed/ refractory aggressive non-Hodgkin's lymphoma. (BioWorld Today)